Parabilis Medicines prices $670 million upsized IPO
Parabilis Medicines priced its upsized IPO at $20.00 per share, offering 33.5 million shares to raise $670 million. A concurrent private placement with Regeneron Pharmaceuticals for 4.17 million shares at $18.00 per share adds $75 million. Trading begins June 10, 2026, on Nasdaq under PBLS.
*this image is generated using AI for illustrative purposes only.
Parabilis Medicines has priced its upsized initial public offering of 33,500,000 shares at $20.00 per share, aiming to raise gross proceeds of $670 million before expenses. The clinical-stage biopharmaceutical company, which focuses on developing medicines for historically undruggable protein targets, granted underwriters a 30-day option to purchase an additional 5,025,000 shares. Trading on the Nasdaq Global Select Market is expected to commence on June 10, 2026, under the ticker symbol PBLS, with the offering closing on or about June 11, 2026.
In a concurrent private placement, Parabilis agreed to sell 4,166,666 shares to Regeneron Pharmaceuticals at $18.00 per share, representing 90% of the IPO price. This transaction is expected to generate approximately $75 million in proceeds and is contingent upon the closing of the IPO, though the IPO is not conditioned on the private placement. The shares sold in the private placement will not be registered under the Securities Act of 1933.
Leerink Partners, BofA Securities, Evercore ISI, and Guggenheim Securities are serving as active book-running managers, while LifeSci Capital LLC acts as passive book-running manager. Registration statements for the offering became effective on June 9, 2026, and are filed with the Securities and Exchange Commission.
Offering Details
| Component | Shares | Price per Share | Gross Proceeds |
|---|---|---|---|
| Initial Public Offering | 33,500,000 | $20.00 | $670 million |
| Underwriters' Option | 5,025,000 | $20.00 | — |
| Concurrent Private Placement | 4,166,666 | $18.00 | $75 million |
Parabilis leverages its proprietary platform to develop Helicons™, stabilized helical peptides designed to modulate proteins beyond the reach of conventional medicines. All shares in the offering are being sold by Parabilis.
How will Parabilis allocate the $745 million in total proceeds across its clinical pipeline and platform development?
What specific milestones does Regeneron expect from the private placement investment, and does it signal a broader partnership?
Will the 10% discount on the private placement shares create significant selling pressure on the stock once trading commences?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
